Every 10-Q that Ovid Therapeutics Inc. (OVID) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OVID and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OVID filings page.
Ovid Therapeutics Inc. reported a larger loss for the quarter ended June 30, 2026 as it increased investment in its neurology pipeline. Revenue was $0.7 million, down sharply from $6.3 million a year earlier, primarily reflecting lower license and other revenue. Net loss for the quarter was $15.0 million versus $4.7 million in the prior-year quarter; for the first six months of 2026 the net loss was $32.0 million.
Operating expenses rose as programs advanced, with research and development spending reaching $10.0 million and general and administrative expenses $6.5 million in the quarter. The company strengthened its balance sheet through equity financings and warrant exercises, resulting in $110.6 million of net cash provided by financing activities in the first half of 2026.
As of June 30, 2026, Ovid held $169.8 million in cash, cash equivalents and marketable securities, up from $90.4 million at year-end 2025, and reported working capital of $113.6 million. Management states this liquidity is expected to fund current operations for at least 12 months from issuance of the financial statements.
Ovid Therapeutics Inc. reported a net loss of $17.0 million for the quarter ended March 31, 2026, wider than the $10.2 million loss a year earlier, as it increased investment in its epilepsy and CNS pipeline. Revenue was minimal, with no license or royalty income recognized this quarter versus $0.1 million in the prior-year period.
Research and development expenses rose to $11.2 million from $6.7 million, mainly driven by higher spending on OV329, the KCC2 library and OV4071. The company strengthened its balance sheet through an October 2025 private placement, warrant exercises, ATM sales and a March 2026 private placement, ending the quarter with $165.6 million in cash, cash equivalents and marketable securities and working capital of $144.4 million. Management believes this liquidity will fund operations for at least 12 months while Ovid advances multiple small-molecule programs for drug-resistant seizures and other brain disorders.
Ovid Therapeutics Inc. reported Q3 2025 results. Revenue was $132k in the quarter and $6.534M year‑to‑date, primarily from license and other revenue. Operating expenses were $12.655M, led by research and development of $5.87M and general and administrative of $6.785M, resulting in a net loss of $12.158M (basic and diluted loss per common share $0.17).
As of September 30, 2025, cash, cash equivalents and marketable securities totaled $25.6M. Net cash used in operating activities was $27.9M for the nine months. Subsequent to quarter‑end, the company closed a private placement of convertible preferred stock and warrants for net proceeds of $75.7M, and stated that available liquidity, including these proceeds, is sufficient to fund operations for more than 12 months after issuance of these financial statements.
Shares outstanding were 71,212,353 as of November 7, 2025.
Ovid Therapeutics Inc. reported unaudited results for the quarter ended June 30, 2025 showing $38.3 million in combined cash, cash equivalents and marketable securities and total assets of $77.4 million, down from $92.2 million at December 31, 2024. Revenue for the three months was $6.3 million versus $0.2 million a year earlier, driven primarily by a $6.3 million payment recognized in connection with the amendment to the Marinus/Immedica arrangement (with $0.7 million recorded as deferred revenue). Operating expenses declined to $11.3 million from $20.7 million, with research and development spending down to $6.5 million and general and administrative to $4.9 million.
The company recorded a net loss of $4.7 million for the quarter and $14.9 million for the six months, and has an accumulated deficit of $319.2 million and working capital of $33.2 million. Management states existing cash and securities are not sufficient to fund current operating plans through the next 12 months and is evaluating strategic alternatives. Takeda discontinued the soticlestat program and prior royalty monetization was reduced to zero; Nasdaq notified the company of a minimum bid deficiency, the company obtained approval to transfer to the Nasdaq Capital Market and authorized a potential reverse stock split option.